MASI

Masimo Corporation

MASI, USA

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, methemoglobin, hemoglobin, fractional arterial oxygen saturation, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow respiratory support therapy, neuromodulation technology, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

https://www.masimo.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MASI
stock
MASI

Masimo (MASI): Evaluating Valuation After Strong Quarter, Philips Expansion and New Credit Facility simplywall.st

Read more →
MASI
stock
MASI

Russell Investments Group Ltd. Trims Stock Position in Masimo Corporation $MASI MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$183.125

Analyst Picks

Strong Buy

4

Buy

2

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

9.30

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-12.40 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-5.52 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

13.70 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.24

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 122.01% of the total shares of Masimo Corporation

1.

BlackRock Inc

(19.3417%)

since

2025/06/30

2.

FMR Inc

(15.0601%)

since

2025/06/30

3.

Politan Capital Management LP

(8.6821%)

since

2025/06/30

4.

Vanguard Group Inc

(8.5378%)

since

2025/06/30

5.

T. Rowe Price Investment Management,Inc.

(4.6022%)

since

2025/06/30

6.

Massachusetts Financial Services Company

(4.5474%)

since

2025/06/30

7.

Capital Research Global Investors

(3.4159%)

since

2025/06/30

8.

MFS Mid Cap Growth Equity

(3.084%)

since

2025/06/30

9.

MFS Mid Cap Growth A

(3.0035%)

since

2025/07/31

10.

Vanguard Total Stock Mkt Idx Inv

(2.8175%)

since

2025/07/31

11.

State Street Corp

(2.7361%)

since

2025/06/30

12.

iShares Core S&P Mid-Cap ETF

(2.6964%)

since

2025/08/31

13.

Fidelity Select Health Care

(2.6286%)

since

2025/07/31

14.

Fidelity Select Medical Tech and Devcs

(2.4851%)

since

2025/07/31

15.

Holocene Advisors, LP

(2.2892%)

since

2025/06/30

16.

American Funds SMALLCAP World A

(2.233%)

since

2025/06/30

17.

BlackRock Mid-Cap Growth Equity Instl

(2.2044%)

since

2025/07/31

18.

Vanguard Small Cap Index

(2.1804%)

since

2025/07/31

19.

Westfield Capital Management Company, L.P.

(2.1743%)

since

2025/06/30

20.

Durable Capital Partners LP

(2.1425%)

since

2025/06/30

21.

Alyeska Investment Group, L.P.

(2.0883%)

since

2025/06/30

22.

BlackRock Global Uncons Eq Z USD Acc

(1.9528%)

since

2025/04/30

23.

Geode Capital Management, LLC

(1.6501%)

since

2025/06/30

24.

AllianceBernstein L.P.

(1.5537%)

since

2025/06/30

25.

Fidelity Advisor Health Care I

(1.4818%)

since

2025/07/31

26.

Strategic Advisers Fidelity US TtlStk

(1.4562%)

since

2025/07/31

27.

Viking Global Investors LP

(1.4127%)

since

2025/06/30

28.

Morgan Stanley - Brokerage Accounts

(1.4126%)

since

2025/06/30

29.

T. Rowe Price US Small-Cap Core Equity

(1.3704%)

since

2025/06/30

30.

Liontrust Investment Partners LLP

(1.3038%)

since

2025/06/30

31.

RTW INVESTMENTS, LLC

(1.2578%)

since

2025/06/30

32.

Vanguard Small Cap Growth Index Inv

(1.2274%)

since

2025/07/31

33.

T. Rowe Price Small-Cap Stock

(1.1862%)

since

2025/07/31

34.

Dimensional Fund Advisors, Inc.

(0.9631%)

since

2025/06/30

35.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8905%)

since

2025/07/31

36.

Goldman Sachs Group Inc

(0.868%)

since

2025/06/30

37.

BlackRock GlbUncons Eq Fd (UK) Z GBPAcc

(0.8677%)

since

2025/04/30

38.

T. Rowe Price US Mid-Cap Growth Equity

(0.7361%)

since

2025/06/30

39.

T. Rowe Price Mid-Cap Growth

(0.7348%)

since

2025/07/31

40.

Fidelity VIP Mid Cap Initial

(0.7326%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

1.44

Latest Release

Date

2025-09-30

EPS Actual

1.32

EPS Estimate

1.2

EPS Difference

0.12

Surprise Percent

10%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.